Peripheral Treg Cell Senescence & Serum Total Cholesterol Level

Tianjin Medical University

Status: Completed

Conditions: Hypercholesterolemia

Study type: Observational

Funder types: Other

Identifiers

NCT05680844

IRB2022-YX-244-01

Details and patient eligibility

About

Hypercholesterolemia is a risk factor for the occurrence and development of atherosclerosis. Recent animal studies have found that increased serum cholesterol level is associated with peripheral Treg cell senescence, but clinical evidence is still lacking. The purpose of this study is to analyze the correlation between human peripheral Treg cell senescence and serum total cholesterol level using clinical blood samples, thus laying a foundation for the establishment of novel therapeutic strategies for atherosclerosis based on the regulation of Treg cell senescence.

Full description

Hypercholesterolemia is a risk factor for the occurrence and development of atherosclerosis. Recent animal studies have found that increased serum cholesterol level is associated with peripheral Treg cell senescence, but clinical evidence is still lacking. The purpose of this study is to analyze the correlation between human peripheral Treg cell senescence and serum total cholesterol level using clinical blood samples, thus laying a foundation for the establishment of novel therapeutic strategies for atherosclerosis based on the regulation of Treg cell senescence.

Enrollment: 200 patients

Sex: All

Ages: 30 to 60 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

1. Age ≥ 30 and ≤ 60 years old with independent behavior ability.
2. The participants need to fully understand the purpose and content of the study, and voluntarily participate in the study and sign the informed consent.

Exclusion criteria

1. Pregnant or lactating women.
2. Acute and severe diseases in the last 3 months, including but not limited to, acute myocardial infarction, acute cerebral infarction, cerebral hemorrhage, circulatory failure, respiratory failure (internal diseases), trauma requiring hospitalization, or undergoes surgery under general anesthesia (surgical diseases).
3. History of severe diseases, including but not limited to, tumors, serious hematological diseases, serious cardiopulmonary diseases (interventional therapy for coronary artery disease, atrial fibrillation, chronic obstructive pulmonary disease, etc.), renal failure, liver failure, old stroke with serious sequelae.
4. Have participated in clinical trials in the past 3 months.
5. The investigator considers that not appropriate for inclusion.

Trial design

200 participants in 2 patient groups

normal cholesterol level group

Description:

Serum total cholesterol level of \< 5.17 mmol/L

hypercholesterolemia group

Description:

Serum total cholesterol level of \>= 5.17 mmol/L